KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $496.0 million.

  • Abbott Laboratories' Capital Expenditures fell 1079.14% to $496.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 178.41%. This contributed to the annual value of $2.2 billion for FY2024, which is 22.71% up from last year.
  • As of Q3 2025, Abbott Laboratories' Capital Expenditures stood at $496.0 million, which was down 1079.14% from $502.0 million recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' Capital Expenditures ranged from a high of $755.0 million in Q4 2023 and a low of $321.0 million during Q1 2022
  • For the 5-year period, Abbott Laboratories' Capital Expenditures averaged around $502.8 million, with its median value being $496.0 million (2025).
  • In the last 5 years, Abbott Laboratories' Capital Expenditures crashed by 3566.98% in 2021 and then surged by 3377.31% in 2023.
  • Over the past 5 years, Abbott Laboratories' Capital Expenditures (Quarter) stood at $614.0 million in 2021, then decreased by 0.65% to $610.0 million in 2022, then rose by 23.77% to $755.0 million in 2023, then dropped by 4.64% to $720.0 million in 2024, then crashed by 31.11% to $496.0 million in 2025.
  • Its last three reported values are $496.0 million in Q3 2025, $502.0 million for Q2 2025, and $484.0 million during Q1 2025.